ProQR spins out Amylon Therapeutics as a privately-held company focused on central nervous system (CNS) therapeutics Press release Key updates September 12, 2017
ProQR’s Drug Candidate QRX-421 for Usher Syndrome Receives Orphan Drug Designation from FDA and EMA Press release Key Updates September 05, 2017
ProQR Strengthens its Scientific Advisory Board with the Appointment of Dr. Phil Zamore, Dr. Cy Stein and Dr. Scott Armstrong Press release Key Updates August 28, 2017
ProQR Announces Results for the Third Quarter of 2016 Press release LEIDEN, the Netherlands, Nov. 14, 2016 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. November 14, 2016
ProQR Announces that QR-010 Meets the Primary Endpoint in a Proof of Concept Study of Homozygous F508del Cystic Fibrosis Patients Press release Topline data to be presented today at NACFC October 27, 2016
ProQR Announces R&D Day and Provides Update on Innovation Portfolio Press release First Investor R&D Day on March 14, 2016 in New York, NY November 30, 2015
ProQR Announces Results for the Second Quarter of 2015 Press release LEIDEN, the Netherlands, Aug. 19, 2015 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. August 19, 2015
ProQR Therapeutics Announces Results for the First Quarter of 2015 Press release LEIDEN, the Netherlands, May 21, 2015 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. May 21, 2015
ProQR Therapeutics Announces Annual Shareholder Meeting Press release LEIDEN, the Netherlands, April 29, 2015 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. April 29, 2015
ProQR Therapeutics Announces Results for the Third Quarter of 2014 Press release LEIDEN, the Netherlands, Nov. 24, 2014 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. November 24, 2014